Over the past decade NuvaRing has proven to be one of the most popular alternatives to oral contraceptives, with use by millions of women worldwide.
However, recent reports from Merck indicate sales may be slowing as experts warn of blood clot risks and more than 1,000 women have filed lawsuits in a federal court.
Last year, both the New England Journal of Medicine and British Medical Journal published studies finding vaginal ring contraceptives like NuvaRing could relate to a 2.5 to 3-fold increased risk of blood clots over traditional pills. Blood clots can cause dangerous conditions like stroke, DVT and pulmonary embolism.
One explanation is that, although NuvaRing claims a lower hormone dose, the constant and direct absorption of these chemicals into the bloodstream can result in higher overall doses for some women.
Brigham and Women’s Faulkner Hospital recently shared a study which found the increased blood clot risks from these devices can be even higher for those women suffering migraines.
So far, more than 1,000 patients have filed a NuvaRing lawsuit in a special federal court in Missouri, and others are pending in New Jersey state court, where Merck is headquartered. In the federal case, trials are scheduled to begin this summer.
Now, Merck’s latest financial statements show the warnings and legal action may be slowing NuvaRing use. According to reports, sales slipped from $168 million to $164 million for the fourth quarter of 2012, a drop of more than 2% from 2011.
There is still time for those injured to file a claim. If you or a loved one suffered blood clots, stroke, DVT or pulmonary embolism after using NuvaRing, it is important to speak with a lawyer about your legal rights as soon as possible.
Due to the specialized nature of defective drug injury cases, DrugRisk only recommends lawyers and law firms who have already handled NuvaRing lawsuits.
For more information on the research, side effects and litigation news related to NuvaRing and other drugs, or to speak with a lawyer, contact us today.